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performed. RESULTS: Incremental cost effectiveness ratios were calculated for
each anti-TNF in comparison to methotrexate. Infliximab is dominated in almost
all scenarios, being more costly and less effective. Etanercept and adalimumab are
the most effective options and most costly. Golimumab appears less effective and
less costly. Sensitivity analysis around utility measure and HAQ improvement as-
sumptions indicate that these are key drivers to the estimates. CONCLUSIONS:
This CUA focuses on novel methods for data inputs estimation. Both Bayesian and
frequentist methods are employed in order to validate the sub models used. The
outputs from the cost utility model show that etanercept and adalimumab appear
most effective on the cost effectiveness plane. However they are also more costly
than both golimumab and certolizumab pegol.
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OBJECTIVES: Falls/Slips cases injured with over the level two and their medical
costs for a year of 2008 at 3 teaching hospitals are explored. METHODS: There are
2559, 1394, and 4086 incident reports in 2008 collected at St. Mary’s Hospital, Shi-
mane University Hospital, and Kyoto University Hospital, Japan. Their reports in-
clude 565, 399, and 561 cases for Falls/Slips. The cases are classified 264, 176, and
306 cases with level 2, and 89, 32, and 82 cases with level 3a, and 8, 3, and 5 cases
with level 3b, respectively. We explored 963 cases with over level 2 in order to
calculate additional medical costs by using their own administrative profiling data.
RESULTS: According to the injury level, average AMCs are 108 at SMH, 175 at SUH
and, 72 USD at KUH (level 2), respectively. Similarly, Average AMCs are 122, 223, and
97 USD (level 3a), and 1,431, 7,745 and 33,357 USD (level 3b), respectively.With
regard to clinical services, AMC with diagnostic imaging is the highest (10,118 USD,
SMH; 14,090 USD, SUH), but AMC with surgery/treatment is the highest at KUH,
92,115 USD. AMC with surgery/treatment is 6900 USD at SMH, and 8879 USD at SUH,
AMC with iv/div is 1275 USD at SMH and 1818 USD at SUH, AMC with laboratory
examination is 674 USD at SMH, and 899 USD at SUH, and AMC with drug admin-
istration is 455 USD at SMH and 318 USD at SUH. By contrast, AMCs at KUH are
11578 USD (imaging), 11290 USD (examination), 3372 USD (drug administration),
and 714 USD (iv/div), because AMC with level 3b and over is the highest by clinical
services. CONCLUSIONS: Therefore, Hospital administrators and policy makers
have to take appropriate measures to prevent patients from Falls/Slips and save
money, because this amount is not overlooked.
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OBJECTIVES: To assess the impact of ankylosing spondylitis (AS) on work produc-
tivity, to determine factors influencing work productivity and to estimate produc-
tivity costs incurred by AS in the Czech Republic. METHODS: A questionnaire in-
cluding Work Productivity and Activity Impairment Questionnaire (WPAI:AS),
Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) were filled out by 230 patients with AS in productive age.
The interdependence between HAQ, BASDAI, disease duration, age and WPAI:AS
scores were described by Spearman=s rank correlation coefficient. We have ana-
lyzed differences between work-active and all patients (work-active  disable)
groups, effect of biological treatment and education level on work productivity.
Productivity costs were calculated by friction cost approach (FCA) using friction
period of 130 work-days and average monthly gross income as denominator.
RESULTS: Average patients= age was 49.3 years (22-61) and average disease dura-
tion 18.0 years. Mean HAQ and BASDAI were 0.99 and 4.43, respectively. We re-
ported significantly greater loss in work productivity (p-value0,001) and daily
activities impairment (p-value0,001) for disable patients in compare to work-
active patients, differences were by 35.6% and 19.6%, respectively. AS in work-
active patients group was associated with 40.7% reduction in work productivity and
40.3% reduction in daily activities. Work-active patients group revealed signifi-
cantly lower age (p-value0,001), lower BASDAI (p-value0,001) and lower HAQ
(p-value0,001). Work absenteeism was weakly correlated with BASDAI and HAQ.
Work presenteeism and overall work impairment were moderately correlated with
BASDAI and HAQ, whereas impairment of daily activities was strongly correlated
with all four WPAI domains. Average annual productivity costs per one patient
were €2923 in all patients group. CONCLUSIONS: HAQ, BASDAI and age signifi-
cantly influence patients’ productivity. Patients on biologics had lower impairment
of daily activities and work productivity and revealed lower HAQ and BASDAI as
well. Average annual productivity costs per one patient were €2923.
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OBJECTIVES: The economic impact of therapeutic non-adherence has been rarely
examined in chronic diseases. This study aims to estimate the impact of non-
adherence with osteoporosis medications on clinical and economic outcomes and
to evaluate the economic value of improving patient compliance using hypotheti-
cal interventions. METHODS: A previously validated Markov microsimulation
model was adapted to the Irish setting to estimate long-term costs and outcomes
(fractures, life years and quality-adjusted life-year (QALY)) for three adherence
scenarios: no treatment, real-world adherence and full adherence over 3 years. The
real-world adherence employed compliance and persistence data from the Irish
HSE-PCRS pharmacy claims database. The number of fractures associated with
poor adherence and the incremental cost per QALY gained between the adherence
scenarios was estimated. We also investigated the cost-effectiveness of hypothet-
ical adherence-enhancing interventions according to their cost and effect on ad-
herence (improvements between 10% and 50%). RESULTS: The number of fractures
prevented and the QALY gain obtained at real-world adherence levels represented
only 57% and 56% of those expected with full adherence, respectively. Over 3 years,
a total number of 3,340 fractures including 1,271 at the hip were estimated to be
associated with non-adherence, resulting in a loss of 3,044 QALYs. The costs per
QALY gained of real-world adherence and of full adherence compared with no
treatment were estimated at €11,834 and €6,341. An intervention to improve ad-
herence by 25% would result in an ICER of €11,392/QALY and €54,182/QALY if the
intervention cost an additional €50 and €100 per year, respectively. CONCLUSIONS:
Poor adherence with osteoporosis medications results in a 50% reduction in the
potential benefits observed in clinical trials and a doubling of the cost per QALY
gained from these medications. Depending on their costs and outcomes, adher-
ence-enhancing interventions have the potential to be an attractive approach to
improve the allocation of resources.
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OBJECTIVES: The present study investigates the treatment persistence of osteopo-
rosis and assesses its impacts on the risk of fractures among women in Taiwan.
METHODS: This is a retrospective cohort study design. Patients who filled prescrip-
tions of alendronate, ibandrobate, risedronate, zoledronate, raloxifene or teripa-
ratide during 2005-2009 were retrieved from the National Health Insurance Re-
search database. Non-persistence was defined when the patients did not refill
prescription within 30 days after the previous osteoporosis prescriptions. Relative
risks of fracture incidence within 3 years after the initial prescription date in four
persistence groups (30 days, 1 month-1 year, 1-2 years, 2-3 years) were evaluated
based upon survival analysis. RESULTS: A total of 1,287,253 patients were included
and followed during the study period of 2005-2009. The overall persistence rates
among patients with osteoporosis drug treatment were 37%, 29%, 21%, and 9% after
1, 2, 3, and 4 years, respectively. Risks of fractures were higher in the lower persis-
tence group (HR 0.87, p0.092 in 1 month-1 year persistence; HR 0.61, p0.001 in 2-3
years persistence). CONCLUSIONS: The relatively high non-persistence rates
among patients with osteoporosis treatment and the significant negative associa-
tion between treatment persistence and fracture incidence indicates potential
cost-savings and health gains are substantial if improvement in the treatment
persistence can be achieved.
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OBJECTIVES: To study self-estimates of rheumatoid arthritis (RA) patients regard-
ing their future health related quality of life and to assess the acceptability of
different health problems at certain stages of life. METHODS: A cross-sectional
survey was performed in 12 rheumatology centres. RA patients initiating first bio-
logical therapy were involved. Disease activity (DAS28) was registered, health sta-
tus (EQ-5D) and functional disability (HAQ-DI) questionnaires were applied. Partic-
ipants were asked to indicate the health status they expect in 3 months time and
for ages 60, 70 and 80 years, using the health problem descriptions of the EQ-5D.
Concerns regarding ”some” and ”severe problems” in the dimensions of the EQ-5D
and HAQ-DI were surveyed by age (acceptable from age 30, 40, 50, 60, 70, 80 or
never). RESULTS: Altogether 116 patients (87.4% females) were involved, mean
(SD): age 52.3 (11.7) years, disease duration 9.3 (8.3) years, DAS28 6.17 (0.89), EQ-5D
score 0.348 (0.358), HAQ-DI 1.476 (0.653). Expected status after 3 months: EQ-5D
0.759 (0.270), HAQ-DI 0.648 (0.593). Patient expect to have significantly worse EQ-5D
scores at ages 60, 70 and 80 than the actual age specific general population has,
mean (SD): 0.438 (0.373) versus 0.728 (0.012); 0.240 (0.406) versus 0.682 (0.016) and
0.070 (0.411) versus 0.615 (0.024), respectively. The majority (26.3%-39.5%) pointed
that ”some problems” in five dimensions of the EQ-5D are acceptable from age 70.
The ”severe problems” level was rejected as never acceptable (54.3%-68.0%) except
the ”usual activities” dimension wherat extreme problems were accepted from age
80 by 47.1%. Similar outcomes were found with the HAQ-DI. CONCLUSIONS: RA
patients initiating biological drug expect quick improvement but prognosticate
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